✕ Headline / Body Mismatch [9/10]: The headline highlights a serious medical concern but uses neutral, factual language without exaggeration. It accurately reflects the article's focus on doctors' concerns about GLP-1 use among people with eating disorders.

"People with eating disorders are taking GLP-1s, and doctors are alarmed"

✕ Appeal to Emotion [2/10]: Uses emotionally resonant patient stories but avoids overt editorializing; quotes convey gravity without the reporter inserting judgment.

"“The past three years have really damaged my life and my health, and I don’t want anyone else to go through this.”"

✕ Appeal to Emotion [3/10]: Describes advertising influence using neutral observation rather than polemic; the jingle anecdote illustrates cultural penetration without loaded commentary.

"Rebecca Boswell, who directs the Princeton Center for Eating Disorders, said she was speaking with a group of eighth-graders about body image when they began singing the Ozempic advertising jingle, in unison. “It was unnerving,” she said."

✕ Loaded Language [4/10]: Characterizes GLP-1s as doing 'the same things that actual anorexia does'—a strong medical comparison that could be seen as loaded, though attributed to a clinician.

"“These medications do the same things that actual anorexia does,” said Wendy Oliver Pyatt..."

✕ Loaded Language [5/10]: Refers to GLP-1s as 'anorexic heroin' in a patient quote, a highly charged metaphor, but clearly attributed and contextualized within personal experience.

"“The apps make it frighteningly easy. It is like anorexic heroin to my brain chemistry,” said Jasper..."

✓ Proper Attribution [9/10]: Includes multiple medical professionals from eating disorder treatment centers with specific titles and affiliations, enhancing credibility.

"Rebecka Peebles, who handles clinical intake for a national eating disorder treatment provider, Monte Nido, as its vice-president of adolescent medicine, said the number of its patients who report using the drugs is rising."

✓ Viewpoint Diversity [8/10]: Quotes representatives from both Novo Nordisk and Eli Lilly, allowing pharmaceutical companies to respond to concerns, even if their responses are non-committal.

"Novo Nordisk, the manufacturer of Ozempic and Wegovy, did not respond directly to whether it believes its drugs are being abused."

✓ Viewpoint Diversity [9/10]: Features personal testimonies from three individuals with lived experience of eating disorders, providing authentic patient perspectives.

"AJ Jasper, 40, has been struggling with anorexia for about 30 years. Three years ago, at a time when he was a healthy weight, he relapsed after purchasing GLP-1s from various apps without ever seeing a doctor."

✕ Vague Attribution [6/10]: Includes the FDA’s standard statement on post-market surveillance, though it does not represent a direct engagement with the specific concern raised.

"The FDA did not directly answer when asked whether it had concerns about the effect of the drugs on people with eating disorders or if it was examining the issue."

✕ Narrative Framing [9/10]: The article frames the issue as a public health and clinical concern rather than a political or commercial story, focusing on patient outcomes and medical ethics.

✕ Framing by Emphasis [8/10]: Emphasizes the psychological and physiological dangers of GLP-1 use in vulnerable populations, prioritizing patient safety over weight-loss efficacy.

"Part of treatment for patients with eating disorders is helping them recognise their natural hunger cues. GLP-1s suppress those cues, providers said, undermining eating disorder treatment."

✕ Narrative Framing [8/10]: Does not present a false balance between pro- and anti-GLP-1 positions but instead centers the voices of clinicians and patients affected by complications.